The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis
Open accessAbstract
Promoting remyelination, a major goal of an effective treatment for demyelinating diseases, has the potential to protect vulnerable axons, increase conduction velocity, and improve neurologic deficits. Strategies to promote remyelination have focused on transplanting oligodendrocytes (OLs) or recruiting endogenous myelinating cells with trophic factors. Ig-based therapies, routinely used to treat a variety of neurological and autoimmune diseases, underlie our approach to enhance remyelination. We isolated two human mAbs directed against OL surface antigens that promoted significant remyelination in a virus-mediated model of multiple sclerosis. Four additional OL-binding human mAbs did not promote remyelination. Both human mAbs were as effective as human i.v. Ig, a treatment shown to have efficacy in multiple sclerosis, and bound to the surface of human OLs suggesting a direct effect of the mAbs on the cells responsible for myelination. Alternatively, targeting human mAbs to areas of central nervous system (CNS) pathology may facilitate the opsonization of myelin debris, allowing repair to proceed. Human mAbs were isolated from the sera of individuals with a form of monoclonal gammopathy. These individuals carry a high level of monoclonal protein in their blood without detriment, lending support to the belief that administration of these mAbs as a therapy would be safe. Our results are ( i ) consistent with the hypothesis that CNS-reactive mAbs, part of the normal Ig repertoire in humans, may help repair and protect the CNS from pathogenic immune injury, and ( ii ) further challenge the premise that Abs that bind OLs are necessarily pathogenic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
Sommer, I., & Schachner, M. (1981) · Developmental Biology · doi:10.1016/0012-1606(81)90477-2 · Cited by 1,134
Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis
Lucchinetti, C. F., Brück, W., Rodriguez, M., & Lassmann, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00854.x · Cited by 733
Self-citationManipulating the Immune System with Immune Globulin
Oates, J. A., Wood, A. J. J., & Dwyer, J. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260206 · Cited by 648
FGF modulates the PDGF-driven pathway of oligodendrocyte development
McKinnon, R. D., Matsui, T., Dubois-Dalcq, M., & Aaronsont, S. A. (1990) · Neuron · doi:10.1016/0896-6273(90)90215-2 · Cited by 597
McTigue, D. M., Horner, P. J., Stokes, B. T., & Gage, F. H. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-14-05354.1998 · Cited by 592
Bögler, O., Wren, D., Barnett, S. C., Land, H., & Noble, M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.16.6368 · Cited by 578
Identification of an adult-specific glial progenitor cell
Wolswijk, G., & Noble, M. (1989) · Development · doi:10.1242/dev.105.2.387 · Cited by 485
Remyelination in multiple sclerosis
Prineas, J. W., & Connell, F. (1979) · Annals of Neurology · doi:10.1002/ana.410050105 · Cited by 454
Repair of demyelinated lesions by transplantation of purified 0-2A progenitor cells
Groves, A. K., Barnett, S. C., Franklin, R. J. M., Crang, A. J., Mayer, M., Blakemore, W. F., & Noble, M. (1993) · Nature · doi:10.1038/362453a0 · Cited by 444
Cited by
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544
“, autoreactive IgM antibodies may constitute a component of endogenous remyelination, and the identification of human monoclonal antibodies has clear therapeutic potentia”
BackgroundImmunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin
Kazatchkine, M. D., & Kaveri, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejmra993360 · Cited by 1,209
Self-citationWhy does remyelination fail in multiple sclerosis?
Franklin, R. J. M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn917 · Cited by 837
Interleukin-1β Promotes Repair of the CNS
Mason, J. L., Suzuki, K., Chaplin, D. D., & Matsushima, G. K. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07046.2001 · Cited by 502
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
Weiner, H. L. (2009) · Annals of Neurology · doi:10.1002/ana.21640 · Cited by 344
Woodruff, R. H., Fruttiger, M., Richardson, W. D., & Franklin, R. J. M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.10.014 · Cited by 335
Keegan, B. M., & Noseworthy, J. H. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103909 · Cited by 319
Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis
Arévalo-Martı́n, Á., Vela, J. M., Molina-Holgado, E., Borrell, J., & Guaza, C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02511.2003 · Cited by 314
Meinl, E., Krumbholz, M., & Hohlfeld, R. (2006) · Annals of Neurology · doi:10.1002/ana.20890 · Cited by 310
Theiler's Virus Infection: a Model for Multiple Sclerosis
Oleszak, E. L., Chang, J. R., Friedman, H., Katsetos, C. D., & Platsoucas, C. D. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.1.174-207.2004 · Cited by 308
Kerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H., & Hohlfeld, R. (2003) · Annals of Neurology · doi:10.1002/ana.10446 · Cited by 273
Nguyen, M. D., D'Aigle, T., Gowing, G., Julien, J.-P., & Rivest, S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4786-03.2004 · Cited by 248
“In addition, numerous studies have reported a protective role of the fine-tuned adaptive immune response (Warrington et al., 2000; Bieber et al., 2001; Kriz et al., 2002; Mitsunaga et al., 2002; Nguyen et al., 2002; Schenk, 2002; Wyss-Coray and Mucke, 2002).”
BackgroundCNS remyelination and inflammation: From basic mechanisms to therapeutic opportunities
Franklin, R. J. M., & Simons, M. (2022) · Neuron · doi:10.1016/j.neuron.2022.09.023 · Cited by 184
Remyelinating strategies for the treatment of multiple sclerosis
Stangel, M., & Hartung, H.-P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00105-3 · Cited by 126
Role of CD5+B-1 cells in EAE pathogenesis
Peterson, L. K., Tsunoda, I., & Fujinami, R. S. (2008) · Autoimmunity · doi:10.1080/08916930801890280 · Cited by 27
Remyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22
Glial cells as therapeutic targets in progressive multiple sclerosis
Wilbanks, B., Maher, L., & Rodriguez, M. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1614443 · Cited by 17
Self-citation
Metadata
- Authors
- Warrington, A. E., Asakura, K., Bieber, A. J., Ciric, B., Van Keulen, V., Kaveri, S. V., Kyle, R. A., Pease, L. R., & Rodriguez, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-06-06
- Volume
- 97
- Issue
- 12
- Pages
- 6820-6825
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1998253454
- Cited by
- 254
- References
- 45
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.